Tridek-One is developing a first-in-class bispecific CD31/TAM agonist antibody to restore immune tolerance. Its approach addresses autoimmune and vascular inflammatory diseases by modulating immune activation through the CD31 pathway.
Location: Paris, France
Board observer: Alexander Demoulin
Website: